Six Unheard Proposals Revealed Here

Six proposals were not heard during the Coordination and Maintenance committee meeting.

The Coordination and Maintenance Committee Meeting was held March 9 – 10, 2021. The meeting began with discussion of the ICD-10-PCS topics. There were six proposals that were not discussed during the meeting which were therapeutic administration of drugs/substances.   This article will review the six proposals.    Remember that all comments for all procedure topics are due April 9, 2021.   The comments should be sent to ICDProcedureCodeRequest@cms.hhs.gov.

The first proposal was for the administration of Amivantamab which is used to treat epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer with Exon20 insertions.   The five-year survival rate is 8 percent with this type of cancer.   This drug is a fully human bispecific antibody that binds to the extracellular domains of the epidermal growth factor and mesenchymal epithelial transition (MET).   It is administered on a 28-day cycle on an outpatient basis.   Patients may need to be administered if admitted for other complications of the disease.  This drug has been designated as a breakthrough therapy and is currently working through clinical trials.

The second proposal is for the administration of Ciltacabtagene Autoleucel which is a B-cell maturation Antigen Directed CAR T-cell Therapy.   This drug treats relapsed/refractory multiple myeloma.   It takes approximately 57 days from registration to complete the initial round of therapy.   There is a PCS code for CAR T-cell therapy, but not specific to this type of therapy.

The third proposal is ENSPRYNG (satralizumab mwge) which is a humanized IgG2 monoclonal antibody which is used for treating Neuromyelitis Optica Spectrum Disorder (NMOSD).   Patients with this disorder relapsed 60% within one year and 90 percent within three years.   These patients required wheelchairs (50 percent) and could be functionally blind (62percent).  In the study, there was significant reduction in relapse.  This medication is given subcutaneously as an inpatient or outpatient.   After a loading dose, the medication is administered every four weeks.

The fourth proposal is administration of Trilaciclib which is a myelopreservation therapy.  The goal of this therapy is to mitigate chemotherapy induced myelosuppression in extensive non-small cell lung cancer patients.  Trilaciclib has been granted FDA breakthrough therapy status.   This medication is administered intravenously or via central line.  Patients are treated with four cycles of 21-day therapy.   The patient is given chemotherapy with Trilaciclib days 1 – 3 followed by 18 days treatment free.   One inpatient admission is expected, but the medication can be administered as an inpatient or outpatient.

The fifth proposal is administration of ZEPZELCA (lurbinectedin) which is a transcription inhibitor for patients with metastatic small cell lung carcinoma.   This is a second line option whose cancer has progressed while on traditional chemotherapy.  This medication has been approved by the Federal Drug Administration (FDA).   The schedule for this medication is every 21 days.   It can be administered on an inpatient or outpatient basis.

The last proposal is the transfusion of pathogen reduced cryoprecipitated fibrinogen complex (PRCFC) which is used to treat massive bleeding when patient is fibrinogen deficient.   This substance is not the same as the usual cryoprecipitate.   This substance has been approved by the FDA and was awarded breakthrough device designation.   PRCFC is treated by INTERCEPT Blood System which inactivates pathogens to reduce transfusion transmitted infections (TTI).   This product has a five-day at room temperature shelf-life.

These six drugs/products have requested New Technology Add-On Payment (NTAP) which provides additional reimbursement to the Medicare-Severity Diagnosis Related Group (MS-DRG).   In proposed rule for Inpatient Prospective Payment System (IPPS) FY22, a preliminary recommendation will be published.    These procedure codes are being considered for FY22 which begins Oct. 1, 2021.

Programming Note: Listen to Laurie Johnson report this story live today during Talk Ten Tuesdays, 10 a.m. Eastern.

 

 

Facebook
Twitter
LinkedIn

Laurie M. Johnson, MS, RHIA, FAHIMA, AHIMA Approved ICD-10-CM/PCS Trainer

Laurie Johnson is currently a senior healthcare consultant for Revenue Cycle Solutions, based in Pittsburgh, Pa. Laurie is an AHIMA-approved ICD-10-CM/PCS trainer. She has more than 35 years of experience in health information management and specializes in coding and related functions. She has been a featured speaker in over 40 conferences. Laurie is a member of the ICD10monitor editorial board and is a permanent panelist on Talk Ten Tuesdays

Related Stories

New Codes Proposed During Two-Day C&M Meeting

New Codes Proposed During Two-Day C&M Meeting

The Coordination and Maintenance (C&M) Committee meeting was held on Sept. 12 and 13. The meeting began with the procedure proposals, which were followed by

Read More

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

I050825

Mastering ICD-10-CM Coding for Diabetes and it’s Complications: Avoiding Denials & Ensuring Compliance

Struggling with ICD-10-CM coding for diabetes and complications? This expert-led webcast clarifies complex combination codes, documentation gaps, and sequencing rules to reduce denials and ensure compliance. Dr. Angela Comfort will provide actionable strategies to accurately link diabetes to complications, improve provider documentation, and optimize reimbursement—helping coders, CDI specialists, and HIM leaders minimize audit risks and strengthen revenue integrity. Don’t miss this chance to master diabetes coding with real-world case studies, key takeaways, and live Q&A!

May 8, 2025

Trending News

Featured Webcasts

Navigating the 3-Day & 1-Day Payment Window: Compliance, Billing, and Revenue Protection

Navigating the 3-Day & 1-Day Payment Window: Compliance, Billing, and Revenue Protection

Struggling with CMS’s 3-Day Payment Window? Join compliance expert Michael G. Calahan, PA, MBA, CCO, to master billing restrictions for pre-admission and inter-facility services. Learn how to avoid audit risks, optimize revenue cycle workflows, and ensure compliance across departments. Critical for C-suite leaders, providers, coders, revenue cycle teams, and compliance teams—this webcast delivers actionable strategies to protect reimbursements and meet federal regulations.

May 15, 2025
Audit-Proof Your Wound Care Procedures: Expert Insights on Compliance and Risk Mitigation

Audit-Proof Your Wound Care Procedures: Expert Insights on Compliance and Risk Mitigation

Providers face increasing Medicare audits when using skin substitute grafts, leaving many unprepared for claim denials and financial liabilities. Join veteran healthcare attorney Andrew B. Wachler, Esq., in this essential webcast and master the Medicare audit process, learn best practices for compliant billing and documentation, and mitigate fraud and abuse risks. With actionable insights and a live Q&A session, you’ll gain the tools to defend your practice and ensure compliance in this rapidly evolving landscape.

April 17, 2025
Utilization Review Essentials: What Every Professional Needs to Know About Medicare

Utilization Review Essentials: What Every Professional Needs to Know About Medicare

Dr. Ronald Hirsch dives into the basics of Medicare for clinicians to be successful as utilization review professionals. He’ll break down what Medicare does and doesn’t pay for, what services it provides and how hospitals get paid for providing those services – including both inpatient and outpatient. Learn how claims are prepared and how much patients must pay for their care. By attending our webcast, you will gain a new understanding of these issues and be better equipped to talk to patients, to their medical staff, and to their administrative team.

March 20, 2025

Rethinking Observation Metrics: Standardizing Data for Better Outcomes

Hospitals face growing challenges in measuring observation metrics due to inconsistencies in classification, payer policies, and benchmarking practices. Join Tiffany Ferguson, LMSW, CMAC, ACM, and Anuja Mohla, DO, FACP, MBA, ACPA-C, CHCQM-PHYADV as they provide critical insights into refining observation metrics. This webcast will address key issues affecting observation data integrity and offer strategies for improving consistency in reporting. You will learn how to define meaningful metrics, clarify commonly misinterpreted terms, and apply best practices for benchmarking, and gain actionable strategies to enhance observation data reliability, mitigate financial risk, and drive better decision-making.

February 25, 2025

Trending News

Celebrate Lab Week with MedLearn! Sign up to win one year of our Laboratory All Access Pass! Click here to learn more →

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24